GlassScriptPhysician profile
Brian T Dam
NPI 1104337054
$675.99
in general payments reported to CMS, 2019-2025
18 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $490 · 2022: $84.17 · 2023: $62.78 · 2024: $39.08.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $102.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $101.86 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Avanir Pharmaceuticals, INC. | $90.48 | 2021 | |
| Astrazeneca Pharmaceuticals LP | $88.76 | 2021 | |
| Stryker Corporation | $62.78 | 2023 | N/A |
| Neo Spine USA, INC. | $42.58 | 2022 | |
| Globus Medical, INC. | $41.59 | 2022 | |
| Jazz Pharmaceuticals INC. | $39.48 | 2021 | |
| Boston Scientific Corporation | $39.08 | 2024 | Wavewriter Alpha Prime 16 |
| Lilly USA, LLC | $34.27 | 2021 | |
| Supernus Pharmaceuticals, INC. | $29.53 | 2021 | |
| Almatica Pharma LLC | $28.40 | 2021 | |
| Mallinckrodt Hospital Products INC. | $24.65 | 2021 | |
| Novartis Pharmaceuticals Corporation | $24.52 | 2021 | |
| Csl Behring | $24.37 | 2021 | |
| Biohaven Pharmaceuticals, INC. | $23.07 | 2021 | |
| Eisai INC. | $22.80 | 2021 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alexion Pharmaceuticals, INC. | $21.83 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $19.24 | 2021 | |
| Lundbeck LLC | $18.56 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brian Dam listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.